Skip to content

Effect of Clcitriol in Ischemi stroke

Evaluating the effect of calcitriol on serum level of inflammatory biomarkers in patients with ischemic stroke

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20210101049905N1
Enrollment
78
Registered
2021-01-15
Start date
2021-01-04
Completion date
Unknown
Last updated
2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Stroke. Cerebral infarction due to thrombosis of unspecified precerebral artery

Interventions

Intervention 1: Intervention group: After diagnosis by the relevant specialist and the existence of inclusion criteria and obtaining consent, patients are randomly divided into two intervention or con

Sponsors

Hamedan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Age 18 to 85 years Focal neurological disorder Clinical diagnosis of acute ischemic stroke Radiological findings of MRI and CT are consistent with the clinical diagnosis of acute hemisphere stroke No other concomitant inflammatory disease Do not take drugs other than standard ischemic stroke treatments that alter the levels of the factors under consideration. No pregnancy and lactation Patients who have been hospitalized for the first 24 hours after a stroke. Patients suffering from ischemic stroke for the first time Do not use any combination with antioxidant effects in the past month No asthma and a history of anaphylactic shock

Exclusion criteria

Exclusion criteria: Evidence based on acute or chronic intracerebral hemorrhage and cerebral aneurysm Existence of any etiology other than ischemia Existence of any cognitive or behavioral disorders that lead to the patient not cooperating. The patient's unwillingness to continue cooperating or taking the drug correctly Drug intolerance and side effects Consumption of any combination or drug with antioxidant effects except prescription drugs

Design outcomes

Primary

MeasureTime frame
Erythrocyte Sedimentation Rate. Timepoint: At the beginning of the study and 3 days after the end of the medication. Method of measurement: Westergren.;C-Reactive Protein. Timepoint: At the beginning of the study and 3 days after the end of the medication. Method of measurement: latex agglutination.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahdi Mahanpoor

Hamedan University of Medical Sciences

mahdymahanpoor@yahoo.com+98 86 3224 2129

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026